Esmolol hydrochloride

Base Information

• Chemical Name: Esmolol hydrochloride
• CAS No.: 81161-17-3
• Molecular Formula: C16H26ClNO4
• Molecular Weight: 331.84
• Hs Code.: 2922199695
• European Community (EC) Number: 636-017-0
• UNII: V05260LC8D
• DSSTox Substance ID: DTXSID7049003
• Wikidata: Q27106523
• NCI Thesaurus Code: C47519
• RXCUI: 203222
• ChEMBL ID: CHEMBL1201115
• Mol file: 81161-17-3.mol

Synonyms:ASL 8052;ASL-8052;Brevibloc;esmolol;esmolol hydrochloride

Chemical Property of Esmolol hydrochloride

Chemical Property:

• Appearance/Colour: white solid
• Melting Point: 48-50 °C
• Boiling Point: 430.2 °C at 760 mmHg
• Flash Point: 214 °C
• PSA: 67.79000
• Density: 1.026 g/cm³
• LogP: 2.72280
• Storage Temp.: −20°C
• Solubility.: H2O: soluble12mg/mL
• Water Solubility.: Slightly soluble
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 10
• Exact Mass: 331.1550360
• Heavy Atom Count: 22
• Complexity: 288

Purity/Quality:

99% ^*data from raw suppliers

Esmolol hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): 52/53:
• Hazard Codes: 52/53:
• Statements: 52/53
• Safety Statements: 61

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O.Cl
• Recent ClinicalTrials: The Impact of Esmolol Administration on Postoperative Recovery
• Recent EU Clinical Trials: Prospective, multicenter and open study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments.
• Description: Esmolol is an ultra-short acting, cardioselective P-blocker with no intrinsic sympathomimetic activity. The capability of rapid reversal makes esmolol uniquely suitable for the acute management of supraventricular tachycardia and the control of blood pressure and heart rate during surgery or other cardiac emergencies.
• Uses: Cardioselective -adrenergic blocker. Antiarrhythmic Esmolol hydrochloride is indicated for paroxysmal supraventricular tachycardia, the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician's judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. antiarrhytmic;cardioselective beta1 receptor blocker
• Therapeutic Function: Beta-adrenergic blocker
• Clinical Use: Beta-adrenoceptor blockerShort-term treatment of supraventricular arrhythmias (including AF, atrial flutter, sinus tachycardia)Tachycardia and hypertension in the perioperative period
• Drug interactions: Potentially hazardous interactions with other drugsAnaesthetics: enhanced hypotensive effect.Analgesics: NSAIDs antagonise hypotensive effect.Anti-arrhythmics: increased risk of myocardial depression and bradycardia; with amiodarone, increased risk of bradycardia and AV block and myocardial depression; increased risk of myocardial depression and bradycardia with flecainide.Antidepressants: enhanced hypotensive effect with MAOIs.Antimalarials: increased risk of bradycardia with mefloquine.Antipsychotics: enhanced hypotensive effect with phenothiazinesCalcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; severe hypotension and heart failure occasionally with nifedipine and possibly other dihydropyridines; asystole, severe hypotension and heart failure with verapamil - avoid concomitant verapamil use.Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers.Cytotoxics: possible increased risk of bradycardia with crizotinib.Diuretics: enhanced hypotensive effect.Fingolimod: possibly increased risk of bradycardia.Moxisylyte: possible severe postural hypotension.Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly dobutamine

Technology Process of Esmolol hydrochloride

There total 4 articles about Esmolol hydrochloride which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 95.6%

methyl 3-<4-(2,3-epoxypropoxy)phenyl>propionate (81147-94-6,246219-23-8) + isopropylamine (75-31-0) → esmolol hydrochloride (81161-17-3)

Guidance literature:

methyl 3-<4-(2,3-epoxypropoxy)phenyl>propionate; isopropylamine; In methanol; at 50 ℃;

With hydrogenchloride; In methanol; ethyl acetate; at 5 ℃; for 1.5h;

Reference yield:

3-(4-hydroxyphenyl)propionic acid methyl ester (5597-50-2) → esmolol hydrochloride (81161-17-3)

Guidance literature:

Multi-step reaction with 2 steps

1: potassium carbonate / acetone / Reflux

2: methanol / Reflux

With potassium carbonate; In methanol; acetone;

DOI:10.1080/00397911.2010.530375

Reference yield:

4-hydroxyphenylpropionic acid (501-97-3) → esmolol hydrochloride (81161-17-3)

Guidance literature:

Multi-step reaction with 3 steps

1: Acidic conditions; Reflux

2: potassium carbonate / acetone / Reflux

3: methanol / Reflux

With potassium carbonate; In methanol; acetone;

DOI:10.1080/00397911.2010.530375

upstream raw materials:

methyl 3-<4-(2,3-epoxypropoxy)phenyl>propionate

isopropylamine

4-hydroxyphenylpropionic acid

3-(4-hydroxyphenyl)propionic acid methyl ester

Downstream raw materials:

3-<4-<2-hydroxy-3-(isopropylamino)propoxy>phenyl>propionic acid hydrochloride

N-isopropyl-3-<4-<2-hydroxy-3-(isopropylamino)propoxy>phenyl>propionamide

3-<4-<2-hydroxy-3-(isopropylamino)propoxy>phenyl>propionic acid

Refernces

• 1、 Zhang, Cunyu A.,Erhardt, Paul W.. "Hitting a soft drug with a hard nucleophile: Preparation of esmolol's metabolite by treatment with bis(tributyltin) oxide". scheme or table. p. 722 - 726. Retrieved 2012/01/13.
• 2、 -. "METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS". . . Retrieved 2008/06/13.